Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective.
The advent of new antiretroviral medicines means that the effects of HIV can now be curbed, but only one in twenty infected people have so far benefited. For those living in developing countries, the new treatments are practically unattainable. Governments, UNAIDS and pharmaceutical companies recognise this only too well and have rethought established assumption in order to try and overcome the challenges posed by cost, inadequate health services and unreliable local supply of medicines.
Cochrane
J
J
Glaxo Wellcome plc, Greenford, UK.
D019380:Anti-HIV Agents / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D001294:Attitude to Health; D003906:Developing Countries; D016527:Drug Costs / Q000706:statistics & numerical data / Q000639:trends; D004345:Drug Industry / Q000458:organization & administration*; D016903:Drug Monitoring / Q000191:economics / Q000592:standards / Q000639:trends; D006076:Government; D015658:HIV Infections / Q000188:drug therapy*; D006297:Health Services Accessibility / Q000191:economics / Q000592:standards* / Q000639:trends; D006801:Humans; D016134:Organizational Policy; D037841:Pregnant People; D014480:United Nations
D019380:Anti-HIV Agents